J.P. Morgan Keeps a Hold Rating on Regeneron (REGN)

In a report issued on May 5, Cory Kasimov from J.P. Morgan maintained a Hold rating on Regeneron (REGNResearch Report). The company’s shares closed last Friday at $599.74.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 20.3% and a 55.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $668.21 average price target, which is a 13.3% upside from current levels. In a report issued on April 28, Citigroup also downgraded the stock to Hold with a $575.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $664.64 and a one-year low of $294.86. Currently, Regeneron has an average volume of 1.19M.

Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Most recently, in August 2020, Christine Poon, a Director at REGN sold 40,000 shares for a total of $24,048,715.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.